E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Hepatitis C virus infection |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008912 |
E.1.2 | Term | Chronic hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the PK Lead-in Phase of this study is:
- To evaluate the steady state pharmacokinetics (PK) and confirm the dose of LDV/SOF FDC in chronic HCV-infected pediatric subjects
The primary objective of the Treatment Phase of this study is:
- To evaluate the safety and tolerability of LDV/SOF FDC for 12 or 24 weeks in chronic HCV-infected pediatric subjects |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the PK Lead-in Phase of this study:
-Evaluate the safety, tolerability, and antiviral activity of 10 days of dosing of LDV/SOF FDC in chronic HCV-infected pediatric subjects
The secondary objectives of the Treatment Phase of this study:
- Determine the antiviral efficacy of 12 or 24 weeks of LDV/SOF FDC treatment in chronic HCV-infected subjects (including the impact of HCV genotype, IL28 genotype, and prior treatment experience)
- Determine the antiviral efficacy of 12 oe 24 weeks of LDV/SOF FDC treatment in chronic HCV-infected subjects
- Evaluate the kinetics of circulating HCV RNA during treatment and after completion of treatment
- Evaluate the emergence of viral resistance to LDV and SOF during treatment and after completion of treatment
- Evaluate the effect of growth and development on pediatric subjects during and after treatment |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
All subjects will be eligible to participate in the Pharmacogenomic (PG) Substudy. For subjects who provide written consent for the PG Substudy, a blood sample will be drawn at the Day 1 visit. If not obtained at Day 1, the sample may be drawn at any time during the study. |
|
E.3 | Principal inclusion criteria |
1. Parent or legal guardian able to provide written informed consent prior to any screening evaluations and willing to comply with study requirements. Subjects will provide assent if possible.
2. 3 years to < 18 years of age as determined at Day 1 (consent of parent or legal guardian required)
3. PK Lead-in only: subjects in Cohort 1 (age 12 to <18 years of age) must weigh ≥ 45 kg
4. PK Lead-in only: all subjects must be treatment naïve: no prior exposure to any IFN, RBV, or other approved or experimental HCV-specific DAA agent
5. Treatment experienced subjects: prior treatment failure to a regimen including interferon either with or without RBV that was completed at least 8 weeks prior to Day 1.
i. Interferon intolerant: Subject who discontinued therapy (≤ 12 weeks total) due to ≥ 1 adverse event
ii. Interferon non-responder: Subject who did not achieve undetectable HCV RNA levels while on treatment
iii. Relapse/breakthrough: Subject who achieved undetectable HCV RNA during treatment or within 4 weeks of the end of treatment but did not achieve a sustained virologic response (SVR)
6. Chronic HCV-infection documented by either:
a) a positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test
at least 6 months prior to the Day 1 visit, or
b) a liver biopsy performed prior to the Day 1 visit with evidence of chronic HCV-infection
7. Infection with HCV as determined at Screening.
8. HCV RNA ≥ 1000 IU/mL at Screening
9. Adequate hematologic function (absolute neutrophil count ≥ 1,500/mm3; hemoglobin ≥ 11 g/dL or ≥ 12 g/dL for GT-3 only ).
10. Negative serum beta-HCG pregnancy test
11. Subject able to provide written assent, if they have the ability to read and write, as determined by IRB/IEC/local requirements and Investigator’s discretion |
|
E.4 | Principal exclusion criteria |
1. Pregnant or lactating subjects
2. Sexually-active males or females of childbearing potential who are not willing to use an effective method of contraception during the study
3. Decompensated liver disease
4. Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency)
5. alpha-fetoprotein > 50 ng/mL
6. Serum creatinine > 1.5 mg/dL
7. Estimated glomerular filtration rate < 90 mL/min/1.73m2, as calculated by the Schwartz Formula
8. Evidence of hepatocellular carcinoma (HCC)
9. Co-infection with HIV, acute HAV, or HBV
10. Significant cardiovascular, pulmonary, or neurological disease
11. Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
12. History of solid organ or bone marrow transplantation
13. Chronic daily non-steroidal anti-inflammatory drug therapy
14. Systemic corticosteroid use for > 2 weeks (pulmonary/nasal administration is permitted)
15. Investigational agents taken within the past 28 days (except with the expressed approval of the Sponsor)
16. Clinically-relevant alcohol or drug abuse within 12 months of screening.
17. Known hypersensitivity to the study drugs, the metabolites, or formulation excipients
18. Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements
19. Use of any prohibited concomitant medications
20. PK Lead-in only: subjects with history of cirrhosis |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- For the PK Lead-in Phase, the appropriateness of the LDV/SOF FDC dose will be assessed by evaluating the steady-state PK of the LDV/SOF FDC. The primary endpoint for determining steady state PK is AUCtau of GS-331007, SOF, and LDV. Additional steady-state PK parameters of GS-331007, SOF, and LDV (e.g., AUClast, Cmax, Tmax, Clast, Tlast, Ctau, λz, CL/F, Vz/F and t½) will be estimated and summarized..
- For the Treatment Phase, the primary safety endpoint is any AE leading to permanent discontinuation of study drug (s). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- In the PK lead in phase 12 weeks data will be collected at screening Day1, Day 3 and Day 10 following Day 10 visits will be as per the treatment phase.
- treatment phase - Screening, Day 1, Week 1, 2, 4, 8 and 12 (and Weeks 16, 20, and 24 for subjects requiring 24 weeks of treatment). AEs will be collected throughout the treatment phase |
|
E.5.2 | Secondary end point(s) |
- For the PK Lead-in Phase, the secondary endpoint will include antiviral activity measurements including assessment of HCV RNA. AEs leading to permanent discontinuation of study drug will be evaluated as a secondary safety endpoint.
- For the Treatment Phase, the key efficacy endpoint is SVR12 and secondary efficacy endpoints include SVR4, SVR24, breakthrough and relapse. Additional efficacy evaluations may include HCV RNA change from Day 1; ALT normalization; and viral kinetic parameters. Secondary safety endpoints of growth and development measurements will be assessed (e.g. height, weight, and Tanner Stage Assessment). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy endpoints at 4 and 24 weeks after treatment end
PK and safety endpoints are accessed during the course of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Australia |
New Zealand |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |